JP2023520647A5 - - Google Patents

Info

Publication number
JP2023520647A5
JP2023520647A5 JP2022557102A JP2022557102A JP2023520647A5 JP 2023520647 A5 JP2023520647 A5 JP 2023520647A5 JP 2022557102 A JP2022557102 A JP 2022557102A JP 2022557102 A JP2022557102 A JP 2022557102A JP 2023520647 A5 JP2023520647 A5 JP 2023520647A5
Authority
JP
Japan
Prior art keywords
methyl
group
methoxy
naphthyridine
methylpyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022557102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520647A (ja
JP7805946B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/052486 external-priority patent/WO2021191838A1/en
Publication of JP2023520647A publication Critical patent/JP2023520647A/ja
Publication of JP2023520647A5 publication Critical patent/JP2023520647A5/ja
Application granted granted Critical
Publication of JP7805946B2 publication Critical patent/JP7805946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022557102A 2020-03-26 2021-03-25 GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体 Active JP7805946B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP2000113 2020-03-26
HUP2000113 2020-03-26
PCT/IB2021/052486 WO2021191838A1 (en) 2020-03-26 2021-03-25 NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Publications (3)

Publication Number Publication Date
JP2023520647A JP2023520647A (ja) 2023-05-18
JP2023520647A5 true JP2023520647A5 (cg-RX-API-DMAC7.html) 2024-03-11
JP7805946B2 JP7805946B2 (ja) 2026-01-26

Family

ID=89666363

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022557102A Active JP7805946B2 (ja) 2020-03-26 2021-03-25 GABA Aアルファ5受容体調節剤としてのナフチリジンおよびピリド[3,4-c]ピリダジン誘導体

Country Status (22)

Country Link
US (1) US12637455B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126859A1 (cg-RX-API-DMAC7.html)
JP (1) JP7805946B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220160061A (cg-RX-API-DMAC7.html)
CN (1) CN115348962A (cg-RX-API-DMAC7.html)
AR (1) AR121666A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021244926B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022019128A2 (cg-RX-API-DMAC7.html)
CA (1) CA3171441A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002568A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014877A2 (cg-RX-API-DMAC7.html)
CU (1) CU24714B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP22082367A (cg-RX-API-DMAC7.html)
GE (2) GEP20257761B (cg-RX-API-DMAC7.html)
IL (1) IL296716A (cg-RX-API-DMAC7.html)
JO (1) JOP20220219A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022011933A (cg-RX-API-DMAC7.html)
PE (1) PE20221836A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552340A1 (cg-RX-API-DMAC7.html)
TW (1) TWI901650B (cg-RX-API-DMAC7.html)
WO (1) WO2021191838A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211414B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
HU231691B1 (hu) * 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
CN116854685A (zh) * 2022-03-28 2023-10-10 上海赛默罗生物科技有限公司 异噁唑-稠环类衍生物、药物组合物和用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237793B (it) 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
FR2728900B1 (fr) * 1994-12-29 1997-01-31 Synthelabo Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique
WO1998050385A1 (en) 1997-05-08 1998-11-12 Merck Sharp & Dohme Limited SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB0017518D0 (en) 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7595395B2 (en) 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
CN101277952B (zh) 2005-10-11 2011-09-28 弗·哈夫曼-拉罗切有限公司 异*唑衍生物
DE602006014185D1 (de) 2005-11-09 2010-06-17 Hoffmann La Roche 3-arylisoxazol-4-carbonylbenzofuranderivative
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
ES2340221T3 (es) 2006-05-24 2010-05-31 Eli Lilly And Company Compuestos y procedimientos para modular fxr.
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
BRPI0812521A2 (pt) 2007-06-13 2015-06-23 Glaxosmithkline Llc Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
US7618973B2 (en) 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
JP5301557B2 (ja) 2007-12-04 2013-09-25 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
KR101354416B1 (ko) 2009-05-07 2014-02-19 에프. 호프만-라 로슈 아게 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체
CN103189062B (zh) 2010-11-05 2016-03-23 霍夫曼-拉罗奇有限公司 活性药物化合物用于治疗中枢神经系统病症的用途
RU2582337C2 (ru) 2010-11-09 2016-04-27 Ф.Хоффманн-Ля Рош Аг Производные триазола в качестве лигандов рецепторов гамк
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
KR20140014205A (ko) * 2011-03-04 2014-02-05 렉시컨 파마슈티컬스 인코퍼레이티드 Mst1 키나제 억제제 및 그의 사용 방법
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
EP2885290B1 (en) 2012-06-26 2017-10-18 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
MX357504B (es) * 2012-06-26 2018-07-12 Saniona Aps Derivado de feniltriazol y su uso para modular complejo del receptor gabaa.
WO2014001278A1 (en) * 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
CN102924452B (zh) * 2012-11-16 2015-01-21 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
EP4032889B1 (en) 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US9296747B1 (en) * 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
CA2990564A1 (en) 2015-06-22 2016-12-29 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic heterocyclic amide derivative
JP2018525429A (ja) 2015-08-28 2018-09-06 アッヴィ・インコーポレイテッド S1p調節剤としての縮合複素環化合物
CN108602811B (zh) 2016-02-01 2021-11-16 轩竹生物科技有限公司 Fxr受体激动剂
EP4129297A1 (en) 2016-03-18 2023-02-08 UWM Research Foundation, Inc. Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with alpha5-containing gabaa receptor agonists
MA48594B1 (fr) 2016-12-08 2022-05-31 Hoffmann La Roche Nouveaux dérivés d'éther d'isoxazolyle en tant que pam alpha5 gaba a
US20200268728A1 (en) * 2016-12-20 2020-08-27 Sumitomo Dainippon Pharma Co., Ltd. Drug targeting cancer stem cell
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
AU2019286312B2 (en) 2018-06-13 2023-08-17 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as GABA A alpha5 PAM
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
BR102019014802A2 (pt) * 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
TWI716107B (zh) 2018-09-26 2021-01-11 美商美國禮來大藥廠 6-氟-2-甲基苯并[d]噻唑-5-基化合物
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators

Similar Documents

Publication Publication Date Title
JP6774513B2 (ja) ムスカリンm1受容体アゴニストとしての二環式アザ化合物
KR101419157B1 (ko) 피라진 유도체 및 신경계 장애의 치료에서의 그의 용도
US10717742B2 (en) Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors
JP6667573B2 (ja) 新規なアミノピリミジン誘導体
ES2346674T3 (es) Compuestos heteroaromaticos de quinolina y su uso como inhibidores de pde10.
JP6325078B2 (ja) ヘテロ環式化合物およびその使用
CN104725359B (zh) 取代的哌嗪化合物及其使用方法和用途
TWI865582B (zh) [1,2,4]三唑并[1,5-c]喹唑啉-5-胺
KR20140084146A (ko) 신규 옥사진 유도체 및 질환의 치료에서의 그의 용도
KR102531689B1 (ko) 6,7―디히드로피라졸로[1,5―α]피라진―4(5H)―온 화합물 및 MGLUR2 수용체의 음성 알로스테릭 조절제로서의 그 용도
US20190142812A1 (en) 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
JP2013523884A5 (cg-RX-API-DMAC7.html)
JP2020526549A5 (cg-RX-API-DMAC7.html)
EP3735411A1 (en) 1, 3, 4, 5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer's disease
BR112015020795B1 (pt) Derivados de pirazol
CN105541693B (zh) 芳杂环类衍生物及其在药物上的应用
RU2019123319A (ru) Пиразолопиримидины и способы их применения
US20240174683A1 (en) Map4k1 inhibitors
JP2017528515A (ja) 6,7−ジヒドロピラゾロ[1,5−a]ピラジン−4(5H)−オン化合物およびMGLUR2受容体の負のアロステリック調節因子としてのそれらの使用
ES2745555T3 (es) Derivados de piperazina y el uso de los mismos como medicamento
US20230023066A1 (en) N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
JP2022502366A5 (cg-RX-API-DMAC7.html)
UA130217C2 (uk) БІЦИКЛІЧНІ ПОХІДНІ ЯК МОДУЛЯТОРИ <font face="Symbol">a</font>5-GABA<sub>A</sub>-РЕЦЕПТОРІВ
JP2009500366A5 (cg-RX-API-DMAC7.html)
HRP20100401T1 (hr) DERIVATI PIRAZOLO/3,4-d/AZEPINA KAO HISTAMINSKI H3 ANTAGONISTI